Relapse and associated risk factors after Mohs micrographic surgery at the Uruguayan national reference University Center

Authors

  • Diego López Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay
  • Julio Magliano Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay
  • Carlos Bazzano Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay

DOI:

https://doi.org/10.47196/da.v27i3.2169

Keywords:

Mohs micrographic surgery, non-melanoma skin cancer, recurrence

Abstract

Background: Mohs micrographic surgery (MMS) is the technique of choice for the treatment of high-risk non-melanoma skin cancer (NMSC). We describe the patient and tumor’s characteristics that define them as high-risk tumors: size, location, being a primary or recurrence tumor, immunological state of the patient, within other factors.

Objective: describe the profile of patients with recurrent carcinomas after MMS in the Dermatology department of Clinic Hospital Dr. Manuel Quintela in a 7-year period.

Methods: observational, descriptive, retrospective, single-center, historical cohort study in which patients with recurrent carcinomas after MMS were analyzed by clinical history revision and results were compared with the literature.

Results: in the mentioned period 7 recurrences within the 388 surgeries were found, corresponding to 1,8% of the surgeries, with a mean time to recurrence of 15,3 +/- 2,3 months. It is highlighted all of them were high risk tumors, 5 were at high risk locations, 3 were immunosupressed and 2 had high risk histological subtypes.

Conclusions: within the 7-year period 1,8% of recurrences after  MMS were found and the mean time to recurrence was 15,3 months. In general, patient’s characteristics were similar to the consulted literature. It is striking the high percentage of smokers and anticoagulated within these patients comparing to all the patiens who completed 5 years of follow-up. However, it is important to take into account that the small number of patients make it difficult to compare the results with other studies.

Author Biographies

Diego López, Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay

Faculty of Medicine, University of the Republic

Julio Magliano, Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay

Adjunct Professor of the Chair of Dermatology, Mohs Surgeon

Carlos Bazzano, Clinical Hospital Dr. Manuel Quintela, Montevideo, Uruguay

Associate Professor of the Chair of Dermatology Chair of Surgical Medical Dermatology

References

I. Benedetto PX, Poblete-López C. Mohs micrographic surgery technique. Dermatol Clin. 2011;29:141-151.

II. Connolly SM, Baker DR, Coldiron BM, Fazio MJ. AAD/ACMS/ ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: A report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Su. J Am Acad Dermatol. 2012;67:531-550.

III. Chen JG, Fleischer AB, Smith ED, Kancler C, et ál. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27:1035-1038.

IV. Van Lee CB, Roorda BM, Wakkee M, Voorham Q, et ál. Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study. Br J Dermatol. 2019;181:338-343.

V. Rowe DE, Carroll RJ, Day CL. Mohs Surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15:424-431.

VI. Flohil SC, Van Der Leest RJT, Arends LR, De Vries E, et ál. Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: A systematic review and meta- analysis. Eur J Cancer. 2013;49:2365-2375.

VII. Asgari MM, Mo et HH, Ray GT, Quesenberry CP. Trends in basal cell carcinoma incidence and identi cation of high-risk subgroups, 1998-2012. JAMA Dermatology. 2015;151:976-981.

VIII. Squamous cell carcinoma NCCN Clinical Practice Guidelines in Oncology. Versión 2.2021. Disponible en: https://www. nccn.org/professionals/physician_gls/pdf/squamous.pdf [Consultado agosto 2021].

IX. Friedman NR. Prognostic factors for local recurrence, metastases, and survival rates in squamous cell carcinoma of the skin, ear, and lip. J Am Acad Dermatol. 1993;28:281-282.

X. Ocampo-Candiani J, Vidaurri LM, Olazarán Medrano Z. Cirugía micrográ ca de Mohs en tumores malignos de piel. Med Cutan Ibero Lat Am. 2004;32:65-70.

XI. Mansouri B, Bicknell LM, Hill D, Walker GD, et ál. Mohs micrographic surgery for the management of cutaneous malignancies. Facial Plast Surg Clin North Am. 2017;25:291-301.

XII. Leitenberger JJ, Rogers H, Chapman JC, Maher IA, et ál. De ning recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: Report of the American College of Mohs Surgery Registry and Outcomes Committee. J Am Acad Dermatol. 2016;75:1022-1031.

XIII. duPlessisPJ,LeventerM,KrekelsG,deWetJD,etál.Outcomes of Mohs Micrographic Surgery at the American Society for Dermatologic Surgery International Traveling Mentorship Program International Mohs Fellowship Recognition Units: A Retrospective Survey of 5889 Cases From South Africa, Romania, and the Net. Dermatol Surg. 2019;45:155-162.

XIV. Kuiper EM, Van den Berge BA, Spoo JR, Kuiper J, et ál. Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases. Clin Otolaryngol. 2018;43:1321-1327.

XV. Van Loo E, Mosterd K, Krekels GAM, Roozeboom MH, et ál. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50:3011-3020.

XVI. Leibovitch I, Huilgol SC, Selva D, Richards S, et ál. Basal cell carcinoma treated with Mohs surgery in Australia II. Outcome at 5-year follow-up. J Am Acad Dermatol. 2005;53:452-457.

XVII. RoweD,CarrollR,DayC.Prognosticfactorsforlocalrecurrence, metastasis and survival rates in SCC of the skin, ear and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976-990.

XVIII. OhY,KimJ,ZhengZ,KimSK,etál.Riskfactorsforrecurrencein cutaneous squamous cell carcinoma after Mohs micrographic surgery: A retrospective review of 237 Asian patients. J Dermatol. 2020;47:72-77.

XIX. Turner RJ, Leonard N, Malcolm AJ, Lawrence CM, et ál. A retrospective study of outcome of Mohs’ micrographic surgery for cutaneous squamous cell carcinoma using formalin xed sections. Br J Dermatol. 2000;142:752-757.

XX. Leibovitch I, Huilgol SC, Selva D, Hill D, et ál. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol. 2005;53:253-260.

XXI. Pugliano-Mauro M, Goldman G. Mohs surgery is e ective for high-risk cutaneous squamous cell carcinoma. Dermatol Surg. 2010;36:1544-1553.

XXII. van der Eerden PA, Prins MEF, Lohuis PJFM, Balm FAJM, et ál. Eighteen years of experience in Mohs micrographic surgery and conventional excision for nonmelanoma skin cancer treated by a single facial plastic surgeon and pathologist. Laryngoscope. 2010;120:2378-2384.

XXIII. FawazB,VieiraC,DeckerA,LawrenceN.Surgicaltreatmentof verrucous carcinoma: a review. J Dermatolog Treat. 2021;1-19.

XXIV. KimDP,KusKJB,RuizE.BasalCellCarcinomaReview.Hematol

Oncol Clin North Am. 2019;33:13-24.

XXV. Basal cell carcinoma NCCN Clinical Practice Guidelines in

Oncology. Versión 2.2021. Disponible en: https://www. nccn.org/professionals/physician_gls/pdf/squamous.pdf [Consultado octubre 2021].

Published

2021-09-18

Issue

Section

Original Articles